Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
Prolia | Denosumab | Osteoporosis, postmenopausal women | List with clinical criteria and/or conditions | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride & dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | List with clinical criteria and/or conditions | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
Lynparza (Resubmission) | Olaparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Avastin | Bevacizumab | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Zejula | Niraparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Complete | ||
Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete |